Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
Plus Therapeutics, Inc. announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to its targeted radiotherapeutic agent REYOBIQ™ for pediatric malignant gliomas, including pediatric ependymoma. This designation offers potential market exclusivity and incentives, supporting the company's ongoing development efforts in CNS cancers with l…